Progress with investigational drugs for the treatment of pulmonary and inflammatory diseases

References

• ISREAL E, DERMARKARIAN R, ROSENBERG M, SPERLING R, TAYLOR G, RUBIN P, DRAZEN JM: The effects of a 5– lipoxygenase inhibitor on asthma induced by cold dry air. New Eng. J. Med. (1990) 323:1740–1744.
   Google Scholar
• SMITH u, GELLER 5, EBRIGHT L, GLASS M, THYRUM PT: Inhibition of the leukotriene 1)4-induced bronchocon-striction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. Am. Rev. Respir. Dis. (1990) 141:988–992.
   PubMed Web of Science ®Google Scholar
• ICE W, ROBERTSON D, SIMMONS D: Mitogen-inducible prostaglandin 6/H synthase: anew target for nonsteroi-dal anti-inflammatory drugs. Drug Development Research (1992) 25:249–265.
   Google Scholar
• COHEN N, YAGALOFF KA: Recent progress in the devel- opment of leukotriene B4 antagonists. Curr. Opin. Invest. Drugs (1994) 3(1):1–10.
   Google Scholar
• SCRIP (1993) 1812:32.
   Google Scholar
• O'SHAUGHNESSY KM, TAYLOR IK, O'CONNER B, O'CON-NELL F, THOMSON H, DOLLERY CT: Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of aller-gen-induced bronchoconstriction. Am. Rev. Respir. Dis. (1993) 147:1431–1435.
   PubMed Web of Science ®Google Scholar
• MAKKER HK, LAU LC, THOMSON HW, BINKS SM, HOL- GATE ST: The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219, against exercise-in-duced asthma_ Am. Rev. Respir. Dis. (1993) 147:1413–1418.
   PubMed Web of Science ®Google Scholar
• SMITH LJ, GLASS M, mimcwrrz Mc: Inhibiton of leulc- otriene 134-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin. Pharmacol. Ther. (1993) 54:430–436.
   PubMed Web of Science ®Google Scholar
• SCRIP (1993) 1852:17.
   Google Scholar
• JACOBS RT, BROWN FJ, CRONK LA, AHARONY D, BUCK-NER CK, KUSNER EJ, KIRKLAND KM, NEILSON KL: Substi-tuted 3-(phenyLmethyl)-1H-indole-5-carboxamides and 1-(phenylmethyflindole-6-carboxamides as potent, se-lective, orally active antagonists of the peptidoleuk-otrienes. J Med. Chem. (1993) 36:394–409.
   PubMed Web of Science ®Google Scholar
• CRAWLEY GC, DOWELL RI, EDWARDS PN, FOSTER SJ, MCMILLAN RM, WALKER ERH, WATERSON D, BIRD TGC, BRUNEAU P, GIRODEAU J-M: Methoxytetrahydropyrans, a new series of selective and orally potent 5-lipoxy-genase inhibitors. J. Med. Chem. (1992) 35:2600–2609.
   PubMed Web of Science ®Google Scholar
• MCMILLAN RM, CRAWLEY GC, WALKER ERH, WILLIAMS AJ,YATES RA, FOSTER SJ: Pharmacological profile and clini-cal status of ICI D2138, a non-redox inhibitor of 5-lipoxygenase. 8th International Conference on Prostaglandins and Related Compounds, Montreal, (1992) Abstr. 132.
   Google Scholar
• MCMILLAN RM, FOSTER SJ: Interactions of cyclooxy-genase inhibitors with non-redox 5-lipoxygenase in-hibitors. World Congress Inflammation '93 Vienna, (1993) Abstr. 25.
   Google Scholar
• CARTER GW, YOUNG PR, ALBERT DH, BOUSKA J, DYERR, BELL RL, SUMMERS JB, BROOKS DW: 5-Lipoxygenase Inhibitory activity of zileuton. J. Pharnzacol Exp. Ther. (1991) 256:929–937.
   PubMed Web of Science ®Google Scholar
• RUBIN P, DUBE L, BRAECKMAN R, SWANSON L, HANSENR, ALBERT D, CARTER G: Pharmacokinetics, safety and ability to diminsh leukotriene synthesis by zileuton, an inhibitor of 5-LO. In: Progress in Inflammation Research and Therapy (1991), Ackerman NR, Bonney RJ, Welton AF (Eds), Verlag, Basel,
   Google Scholar
• COLLAWN C, RUBIN P, PEREZ H, BOBADILLA J, CABRERA G, REYES E, BOROVOY J, KERSHENOBICH D: Phase II study of the safety and efficacy of a 5-lipoxygenase Inhibitor in patients with ulcerative colitis. Am. J. Gas-teroentera (1992) 87:342–346.
   PubMed Web of Science ®Google Scholar
• KNAPP HR: Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. New Eng.J. Med. (1990) 323:1745–1748.
   PubMed Web of Science ®Google Scholar
• ISREAL E, RUBIN P, KEMO JP, GROSSMAN J, PIERSON W, SIEGEL SC, TINKELMAN D, MURRAY JJ, BUSSE W, SEGAL AT, FISH J, KAISER HB, LEDFORD D, WENZEL S, ROSEN-THAL R, COHN J, LANNI C, PEARLMAN H, KARAHALIOS P, DRAZEN JM: The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann. Intern. Med. (1993) 119:1059–1066.
   PubMedGoogle Scholar
• ISREAL E, FISCHER AR, ROSENBERG MW, LILLY CM, CAL- LERY JC, SHAPIRO J, COHN J, RUBIN P, DRAZEN JM: Thepivitol role of 5-11poxygenase products in the reactions of aspirin-sensitive asthmatics to aspirin. Am. Rev. Respir. Dis. (1993) 148:1447–1451.
   PubMedGoogle Scholar
• CHRISTIE PE, TAGARI P, FORD-HUTCHINSON AW, Ch AR-LESSON S, CHEE P, ARM JP, LEE TH: Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am. Rev. Respir. Dis. (1991) 143:1025–1029.
   PubMed Web of Science ®Google Scholar
• BROOKS DW, STEWART AO, BHAT1A P, MARTIN J, BASHA A, KERKMAN D, BELL RE, BOUSKA J, LANNI C, YOUNG PR, MALO PE, RUBIN P, CARTER GW: Second generation leukotriene biosynthesis inhibitors. 204th ACS Meeting Washington, DC, (1992) MEDI 17.
   Google Scholar
• BELL RE, BROOKS DW, YOUNG PR, LANNI C, STEWART AO, BOUSKA J, MALO PE, CARTER GW: A-78773: a selec-tive, potent 5-lipoxygenase inhibitor. J. Lipid Mediators (1993) 6:259–264.
   PubMed Web of Science ®Google Scholar
• RUBIN PD, DUBE LM, WINKELMAN LG, COHN J, BRAND-WEIN R: Zileuton, a 5-lipoxygenase inhibitor, efficacy in human clinical trials. 8th International Conference on Prostaglandins and Related Compounds, Montreal, (1992) Abstr. 638.
   Google Scholar
• LANNI C, FORT J, OTIS E, WILEY Y, ALBERT D, STEWART AO, BELL RE, SUMMERS JB, BROOKS DW, CARTER GW: Characterization of inhibition of 5-lipoxygenase en-zyme by N-hydroxyureas. World Congress Inflammation '93, (1993) Abstr. 26.
   Google Scholar
• HATZELMANN A, FRUCHTMANN R, MOHRS K, RADDATZ S, MULLER-PEDDINGHAUS R: Mode of action of new selective leukotriene biosynthesis inhibitor, BAY X 1005 and structurally related compounds. Biochemical Pharmacology (1993) 45:101–11.
   PubMed Web of Science ®Google Scholar
• FRUCHTMANN R, MOHRS K, HATZELMANN A, RADDATZ S, FUGMANN B, JUNGE B, MULLER-PEDDINGHAUS R: In vitro pharmacology of BAY X 1005, a new inhibitor of leukotriene synthesis. Agents and Actions (1993) 38:188–195.
   PubMedGoogle Scholar
• MULLER-PEDDINGHAUS R, FRUCHTMANN R, AHR BECKERMANN B, BUHNER K, FUGMANN B, JUNGE B, MATZKE M, KOHLKSDORFER C, RADDATZ S, THEISEN-POPP P, MOHRS H: BAY X 1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharma-cokinetics. I Lipid Mediators (1993) 6:245–248.
   PubMedGoogle Scholar
• DAHLEN 5, DAHLEN B, IHRE I, KUMLIN M, FRANZEN L,STENSVAD F, LARSSON C, BLOMQVIST H, BJORCK T, ZE 1 'EKSTROM O: The leukotriene biosynthesis inhibi-tor BAY X 1005 is a potent inhibitor of allergen-induced airway obstruction and leukotriene formation in man. Am. Rev. Respir. flier. (1993) 147:A837.
   Google Scholar
• SCRIP (1993) 1879:23.
   Google Scholar
• BRIDEAU C, CHAN C, CHARLESON S, DENIS D, EVANS JF,FORD-HUTCHINSON AW, FORTIN AW, GILLARD JW, GUAY J, GUEVREMONT D, HUTCHINSON JH, JONES TR, LEGER S, MANCINI JA, MCFARLANE CS, PICKETT C, PIED-HUTA H, PRASIT P, RIENDEAU D, ROUZER CA, TAGARI P, VICKERS PJ, YOUNG RN: Pharmacology of MK-0591 (341-(4-cholorobenzy1)-3-(t-butylthio)-5-(quinolin-2-y lmethoxy)indol-2-y11-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pbarmacol. (1992) 70:799–807.
   PubMed Web of Science ®Google Scholar
• TANAKA W, DALLOB A, FRIEDMAN BS, BRECHER EB, SEIBOLD, JR: Biochemical activity of a potent, orally active, leukotriene biosynthesis inhibitor (MK-0591) in healthy male volunteers. 8th International Conference on Prostaglandins and Related Compounds, Montreal, (1992) Abstr. 643.
   Google Scholar
• DEPRE M, VANHECKEN A, FRIEDMAN B, TANAKA W, SHINGO S, BUNTINX A, DESCHEPPER P: Pharmacokinet-ics and pharmacodynamics of multiple oral doses of MK-0591, a FLAP inhibitor. 3rd International Conference on Lipid Mediators in Health and Disease, Jerusalem (1993) Abstr. PII–4.
   Google Scholar
• CHERVINSKY P, FRIEDMAN B, O'NEILL T, RIVARD S, TANAKA W, TEAHANJ, ZHANG J: Biochemical effects of MK-0591, a potent oral leukotriene biosynthesis inhibi-tor in patients with mild asthma./ Allergy Clin . Immunol. (1993) 91:225.
   Web of Science ®Google Scholar
• SCRIP (1993) 1817:13.
   Google Scholar
• LAZER ES, MIAO CK, WONG H-C, SORCEK R, SPERO DM,GRAHAM AG, WATROUS JM, HOMON C, PARKS TP, HOFF-MAN AF, GUNDEL RH, FARINA PR, ADAMS J: Benzoxazo-lamines and benzothiazolamines: potent enantloselective inhibitors of leukotriene biosynthesis with a novel mechanism of action. 206th ACS National Meeting Chicago (1993) MEDI 23.
   Google Scholar
• FARINA PR, GRAHAM AG, HOFFMAN AF, WATROUS JM, BORGEAT P, LETTS LG, HANSEN G, DINALLO RM, ADAMS J, MIA° CK, LAZER ES, PARKS TP, HOMON CA: Identifica-tion of a novel inhibitor of arachidonate release which blocks LTB4 and PAP biosynthesis in human neutro-phils. 3rd International Conference on Lipid Mediators in Health and Disease, Jerusalem (1993) p26.
   Google Scholar
• VERPOOTEN GA, DEPRE M, BRUNNER F, JURGENS A, POUSSET V, CHOW A, RUBIN E, BALDAUF C, ARNOUT J, DESCHEPPER P, DEBROE ME: 5-LO inhibition profile after multiple dose tepoxalin. 3rd International Confer-ence on Lipid Mediators in Health and Disease, Jerusalem (1993) p79.
   Google Scholar
• MEADE EA, SMITH AXIL, DEWITT DL: Differential inhibi- tion of prostaglandin endoperoxide synthase (cy-clooxygenase) isoenzymes by aspirin and other non-steroidal anti-inflanunatory drugs. J. Biol. Chem. (1992) 268:6610–6614.
   Google Scholar
• MITCHELL JA, AKARASEREENONT P, THIEMERMANN C, VANE JR: Differential effects of nonsteroid anti-inflam-matory drugs on cyclooxygenase present in endothelial cells (COX-1) and in LPS-activated macrophages (COX-2). World Congress Inflammation '93 Vienna (1993) Abstr. P58
   Google Scholar
• DEWITT DL, LANEUVILLE O, LECOMTE HLA, FUNK C, SMITH WL: Selective inhibition of the human PGII synthase-1 and -2 (cydooxygenase) isoenzymes by as-pirin and other non-steroidal anti-inflammatory drugs. World Congress Inflammation '93 Vienna (1993), Abstr. 119.
   Google Scholar
• FURAIU N, TAKAHASHI S, YOKOYAMA M, ARAI I, HIGUCHIS, OTOMO S: An antlinflammatory agent, NS-398, selec-tively inhibits PGHS-1 activity in rat endotoxin-induced shock. World Congress Inflammation '93 Vienna (1993) Abstr. 154.
   Google Scholar